Fruquintinib: First Global Approval

被引：93

作者：

Shirley, Matt ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2018年 / 78卷 / 16期

关键词：

METASTATIC COLORECTAL-CANCER; TYROSINE KINASES; VEGFR INHIBITOR; PHASE-I; PHARMACOKINETICS; SAFETY; POTENT;

D O I：

10.1007/s40265-018-0998-z

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Fruquintinib (Elunate(A (R))) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours. In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies. Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer. This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.

引用

页码：1757 / 1761

页数：5

共 10 条

[1] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors [J].

Cao, Junning ;

Zhang, Jian ;

Peng, Wei ;

Chen, Zhiyu ;

Fan, Songhua ;

Su, Weiguo ;

Li, Ke ;

Li, Jin .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) :259-269

[2] Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial [J].

Li, Jin ;

Qin, Shukui ;

Xu, Rui-Hua ;

Shen, Lin ;

Xu, Jianming ;

Bai, Yuxian ;

Yang, Lei ;

Deng, Yanhong ;

Chen, Zhen-dong ;

Zhong, Haijun ;

Pan, Hongming ;

Guo, Weijian ;

Shu, Yongqian ;

Yuan, Ying ;

Zhou, Jianfeng ;

Xu, Nong ;

Liu, Tianshu ;

Ma, Dong ;

Wu, Changping ;

Cheng, Ying ;

Chen, Donghui ;

Li, Wei ;

Sun, Sanyuan ;

Yu, Zhuang ;

Cao, Peiguo ;

Chen, Haihui ;

Wang, Jiejun ;

Wang, Shubin ;

Wang, Hongbing ;

Fan, Songhua ;

Hua, Ye ;

Su, Weiguo .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (24) :2486-2496

[3]

Li K, 2018, CLIN PHARMACOL THER, V103, pS86

[4] Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell Lung Cancer [J].

Lu, Shun ;

Chang, Jianhua ;

Liu, Xiaoqing ;

Shi, Jianhua ;

Lu, You ;

Li, Wei ;

Yang, Jin-ji ;

Zhou, Jianying ;

Wang, Jie ;

An, Tongtong ;

Yang, Lei ;

Liu, Zhe ;

Zhou, Xiangdong ;

Chen, Mo ;

Hua, Ye ;

Su, Weiguo .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) :1207-+

[5] Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models [J].

Ren, Yongxin ;

Sun, Qiaoling ;

Long, Jingwen ;

Fan, Shiming ;

Tang, Renxiang ;

Zhang, Wei ;

Ge, Xuelei ;

Tang, Jianxing ;

Wang, Linfang ;

Shi, Dongxia ;

Chen, Hongbo ;

Cheng, Min ;

Qing, Weiguo ;

Su, Weiguo .

CANCER RESEARCH, 2017, 77

[6] Monoclonal Antibodies in Cancer Therapy [J].

Zahavi, David ;

Weiner, Louis .

ANTIBODIES, 2020, 9 (03) :1-20

[7] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy [J].

Sun, Qiaoling ;

Zhou, Jinghong ;

Zhang, Zheng ;

Guo, Mingchuan ;

Liang, Junqing ;

Zhou, Feng ;

Long, Jingwen ;

Zhang, Wei ;

Yin, Fang ;

Cai, Huaqing ;

Yang, Haibin ;

Zhang, Weihan ;

Gu, Yi ;

Ni, Liang ;

Sai, Yang ;

Cui, Yumin ;

Zhang, Meifang ;

Hong, Minhua ;

Sun, Junen ;

Yang, Zheng ;

Qing, Weiguo ;

Su, Weiguo ;

Ren, Yongxin .

CANCER BIOLOGY & THERAPY, 2014, 15 (12) :1635-1645

[8] Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study [J].

Xu, Rui-Hua ;

Li, Jin ;

Bai, Yuxian ;

Xu, Jianming ;

Liu, Tianshu ;

Shen, Lin ;

Wang, Liwei ;

Pan, Hongming ;

Cao, Junning ;

Zhang, Dongsheng ;

Fan, Songhua ;

Hua, Ye ;

Su, Weiguo .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 :1-8

[9] Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways [J].

Zhong, Haizhen ;

Bowen, J. Phillip .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (12) :1571-1590

[10] A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers [J].

Zhou, Sufeng ;

Shao, Feng ;

Xu, Zhaoqiang ;

Wang, Lu ;

Jin, Ke ;

Xie, Lijun ;

Chen, Juan ;

Liu, Yun ;

Zhang, Hongwen ;

Ou, Ning .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) :563-573

← 1 →